Korean J Gastroenterol KJG The Korean Journal of Gastroenterology 1598-9992 2233-6869 The Korean Society of Gastroenterology 10.4166/kjg.2019.74.2.87 Special Review Supportive and Palliative Care of Pancreatic Cancer Nutritional Support for Patients with Pancreatic Cancer https://orcid.org/0000-0001-8749-408X Jung Min Kyu 1 2 Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea. Correspondence to: Min Kyu Jung, Department of Internal Medicine, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Jung-gu, Daegu 41944, Korea. Tel: +82-53-200-5514, Fax: +82-53-426-8773, minky1973@knu.ac.kr 08 2019 27 08 2019 74 2 87 94 17 07 2019 29 07 2019 01 08 2019 Copyright © 2019. Korean Society of Gastroenterology 2019 Korean Society of Gastroenterology This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pancreatic cancer is the ninth common malignancy in South Korea. It has a dismal prognosis with a 5-year overall survival rate of less than 10%, and pancreatic cancer is associated with cancer cachexia, which is defined as the loss of muscle mass that is not reversible by conventional nutritional support. Cachexia is noted in over 85% of all pancreatic cancer patients and it is strongly related with the disease’s mortality. Nearly 30% of pancreatic cancer deaths are due to cachexia rather than being due to the tumor burden. Therefore, it is crucial to discover the mechanisms behind the development of muscle wasting in pancreatic cancer patients and find novel therapeutics for targeting cachexia. This review deals with the current understanding about the development of cachexia and nutritional support in those patients suffering with pancreatic cancer.

 Nutritional support Pancreatic neoplasms Cachexia

None.

None.

 Von Hoff DD Ervin T Arena FP Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 2013 369 1691 1703 Koutsounas I Giaginis C Patsouris E Theocharis S Current evidence for histone deacetylase inhibitors in pancreatic cancer World J Gastroenterol 2013 19 813 828 Kneuertz PJ Cunningham SC Cameron JL Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience J Gastrointest Surg 2011 15 1917 1927 Wigmore SJ Plester CE Richardson RA Fearon KC Changes in nutritional status associated with unresectable pancreatic cancer Br J Cancer 1997 75 106 109 Gärtner S Krüger J Aghdassi AA Nutrition in pancreatic cancer: a review Gastrointest Tumors 2016 2 195 202 Fearon KC Baracos VE Cachexia in pancreatic cancer: new treatment options and measures of success HPB (Oxford) 2010 12 323 324 Kyle UG Pirlich M Lochs H Schuetz T Pichard C Increased length of hospital stay in underweight and overweight patients at hospital admission: a controlled population study Clin Nutr 2005 24 133 142 Bachmann J Heiligensetzer M Krakowski-Roosen H Büchler MW Friess H Martignoni ME Cachexia worsens prognosis in patients with resectable pancreatic cancer J Gastrointest Surg 2008 12 1193 1201 Evans WJ Morley JE Argilés J Cachexia: a new definition Clin Nutr 2008 27 793 799 Bachmann J Ketterer K Marsch C Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function BMC Cancer 2009 9 255 Felix K Fakelman F Hartmann D Identification of serum proteins involved in pancreatic cancer cachexia Life Sci 2011 88 218 225 Fearon K Strasser F Anker SD Definition and classification of cancer cachexia: an international consensus Lancet Oncol 2011 12 489 495 Skipworth RJ Stewart GD Dejong CH Preston T Fearon KC Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007 26 667 676 Stewart GD Skipworth RJ Fearon KC Cancer cachexia and fatigue Clin Med (Lond) 2006 6 140 143 Metter EJ Conwit R Tobin J Fozard JL Age-associated loss of power and strength in the upper extremities in women and men J Gerontol A Biol Sci Med Sci 1997 52 B267 B276 Fearon KC Glass DJ Guttridge DC Cancer cachexia: mediators, signaling, and metabolic pathways Cell Metab 2012 16 153 166 Mace TA Ameen Z Collins A Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner Cancer Res 2013 73 3007 3018 Argilés JM Busquets S Stemmler B López-Soriano FJ Cachexia and sarcopenia: mechanisms and potential targets for intervention Curr Opin Pharmacol 2015 22 100 106 Martignoni ME Kunze P Hildebrandt W Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia Clin Cancer Res 2005 11 5802 5808 Denley SM Jamieson NB McCall P Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma J Gastrointest Surg 2013 17 887 898 Mitsunaga S Ikeda M Shimizu S Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer Br J Cancer 2013 108 2063 2069 Pop VV Seicean A Lupan I Samasca G Burz CC IL-6 roles - molecular pathway and clinical implication in pancreatic cancer - a systemic review Immunol Lett 2017 181 45 50 Farren MR Mace TA Geyer S Systemic immune activity predicts overall survival in treatment-naïve patients with metastatic pancreatic cancer Clin Cancer Res 2016 22 2565 2574 Zhou W Jiang ZW Tian J Jiang J Li N Li JS Role of NF-kappaB and cytokine in experimental cancer cachexia World J Gastroenterol 2003 9 1567 1570 Bonetto A Aydogdu T Jin X JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia Am J Physiol Endocrinol Metab 2012 303 E410 E421 Bonetto A Aydogdu T Kunzevitzky N STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia PLoS One 2011 6 e22538 Guttridge DC Mayo MW Madrid LV Wang CY Baldwin AS Jr NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia Science 2000 289 2363 2366 Zhang L Tang H Kou Y MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia J Cancer Res Clin Oncol 2013 139 1105 1115 Melstrom LG Melstrom KA Jr Ding XZ Adrian TE Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia Histol Histopathol 2007 22 805 814 Fogelman DR Morris J Xiao L A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients Support Care Cancer 2017 25 1809 1817 McPherron AC Lawler AM Lee SJ Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member Nature 1997 387 83 90 Chen YG Wang Q Lin SL Chang CD Chuang J Ying SY Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis Exp Biol Med (Maywood) 2006 231 534 544 Sartori R Milan G Patron M Smad2 and 3 transcription factors control muscle mass in adulthood Am J Physiol Cell Physiol 2009 296 C1248 C1257 Loumaye A de Barsy M Nachit M Role of activin A and myostatin in human cancer cachexia J Clin Endocrinol Metab 2015 100 2030 2038 Zhou X Wang JL Lu J Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival Cell 2010 142 531 543 Togashi Y Kogita A Sakamoto H Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer Cancer Lett 2015 356 2 Pt B 819 827 Greco SH Tomkötter L Vahle AK TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia PLoS One 2015 10 e0132786 Miyamoto Y Hanna DL Zhang W Baba H Lenz HJ Molecular pathways: cachexia signaling-a targeted approach to cancer treatment Clin Cancer Res 2016 22 3999 4004 Calnan DR Brunet A The FoxO code Oncogene 2008 27 2276 2288 Schmitt TL Martignoni ME Bachmann J Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia J Mol Med (Berl) 2007 85 647 654 Avan A Avan A Le Large TY AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients PLoS One 2014 9 e108057 Sacheck JM Ohtsuka A McLary SC Goldberg AL IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 Am J Physiol Endocrinol Metab 2004 287 E591 E601 Abbott CR Monteiro M Small CJ The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway Brain Res 2005 1044 127 131 Kim SY Park SM Lee ST Apolipoprotein C-II is a novel substrate for matrix metalloproteinases Biochem Biophys Res Commun 2006 339 47 54 Russell ST Zimmerman TP Domin BA Tisdale MJ Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein Biochim Biophys Acta 2004 1636 59 68 Ronga I Gallucci F Riccardi F Uomo G Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach Adv Med Sci 2014 59 1 6 Uomo G Gallucci F Rabitti PG Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management JOP 2006 7 157 162 Ramos EJ Suzuki S Marks D Inui A Asakawa A Meguid MM Cancer anorexia-cachexia syndrome: cytokines and neuropeptides Curr Opin Clin Nutr Metab Care 2004 7 427 434 Mueller TC Burmeister MA Bachmann J Martignoni ME Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol 2014 20 9361 9373 Sikkens EC Cahen DL de Wit J Looman CW van Eijck C Bruno MJ Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function Br J Surg 2014 101 109 113 Hackert T Schütte K Malfertheiner P The pancreas: causes for malabsorption Viszeralmedizin 2014 30 190 197 Kanda M Fujii T Kodera Y Nagai S Takeda S Nakao A Nutritional predictors of postoperative outcome in pancreatic cancer Br J Surg 2011 98 268 274 Loh KW Vriens MR Gerritsen A Unintentional weight loss is the most important indicator of malnutrition among surgical cancer patients Neth J Med 2012 70 365 369 La Torre M Ziparo V Nigri G Cavallini M Balducci G Ramacciato G Malnutrition and pancreatic surgery: prevalence and outcomes J Surg Oncol 2013 107 702 708 Billingsley KG Hur K Henderson WG Daley J Khuri SF Bell RH Jr Outcome after pancreaticoduodenectomy for periampullary cancer: an analysis from the veterans affairs national surgical quality improvement program J Gastrointest Surg 2003 7 484 491 Gibbs J Cull W Henderson W Daley J Hur K Khuri SF Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the national VA surgical risk study Arch Surg 1999 134 36 42 Augustin T Burstein MD Schneider EB Frailty predicts risk of life-threatening complications and mortality after pancreatic resections Surgery 2016 160 987 996 Imaoka H Mizuno N Hara K Evaluation of modified glasgow prognostic score for pancreatic cancer: a retrospective cohort study Pancreas 2016 45 211 217 Lucas DJ Schexneider KI Weiss M Trends and risk factors for transfusion in hepatopancreatobiliary surgery J Gastrointest Surg 2014 18 719 728 Sikkens EC Cahen DL de Wit J Looman CW van Eijck C Bruno MJ A prospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor J Clin Gastroenterol 2014 48 e43 e46 Lindkvist B Phillips ME Domínguez-Muñoz JE Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: prevalence and diagnostic use Pancreatology 2015 15 589 597 Roeyen G Jansen M Chapelle T Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study Pancreatology 2016 16 671 676 Illés D Terzin V Holzinger G New-onset type 2 diabetes mellitus--a high-risk group suitable for the screening of pancreatic cancer? Pancreatology 2016 16 266 271 Gupta S Vittinghoff E Bertenthal D New-onset diabetes and pancreatic cancer Clin Gastroenterol Hepatol 2006 4 1366 1372 Pannala R Leirness JB Bamlet WR Basu A Petersen GM Chari ST Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus Gastroenterology 2008 134 981 987 Giovannucci E Michaud D The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas Gastroenterology 2007 132 2208 2225 Hart PA Baichoo E Bi Y Hinton A Kudva YC Chari ST Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus Pancreatology 2015 15 162 166 Cooperman AM Chivati J Chamberlain RS Nutritional and metabolic aspects of pancreatic cancer Curr Opin Clin Nutr Metab Care 2000 3 17 21 Klek S Sierzega M Szybinski P The immunomodulating enteral nutrition in malnourished surgical patients - a prospective, randomized, double-blind clinical trial Clin Nutr 2011 30 282 288 Gianotti L Braga M Gentilini O Balzano G Zerbi A Di Carlo V Artificial nutrition after pancreaticoduodenectomy Pancreas 2000 21 344 351 Di Carlo V Gianotti L Balzano G Zerbi A Braga M Complications of pancreatic surgery and the role of perioperative nutrition Dig Surg 1999 16 320 326 Karagianni VT Papalois AE Triantafillidis JK Nutritional status and nutritional support before and after pancreatectomy for pancreatic cancer and chronic pancreatitis Indian J Surg Oncol 2012 3 348 359 Park JS Chung HK Hwang HK Kim JK Yoon DS Postoperative nutritional effects of early enteral feeding compared with total parental nutrition in pancreaticoduodectomy patients: a prosepective, randomized study J Korean Med Sci 2012 27 261 267 Liu C Du Z Lou C Enteral nutrition is superior to total parenteral nutrition for pancreatic cancer patients who underwent pancreaticoduodenectomy Asia Pac J Clin Nutr 2011 20 154 160 Park JW Jang JY Kim EJ Effects of pancreatectomy on nutritional state, pancreatic function and quality of life Br J Surg 2013 100 1064 1070 Nussbaum DP Zani S Penne K Feeding jejunostomy tube placement in patients undergoing pancreaticoduodenectomy: an ongoing dilemma J Gastrointest Surg 2014 18 1752 1759 Richter E Denecke A Klapdor S Klapdor R Parenteral nutrition support for patients with pancreatic cancer--improvement of the nutritional status and the therapeutic outcome Anticancer Res 2012 32 2111 2118 Pelzer U Arnold D Gövercin M Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study BMC Cancer 2010 10 86 Vashi PG Dahlk S Popiel B Lammersfeld CA Ireton-Jones C Gupta D A longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition BMC Cancer 2014 14 593 Davidson W Ash S Capra S Bauer J Cancer Cachexia Study Group Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer Clin Nutr 2004 23 239 247 Wigmore SJ Barber MD Ross JA Tisdale MJ Fearon KC Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer Nutr Cancer 2000 36 177 184 Fearon KC Von Meyenfeldt MF Moses AG Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial Gut 2003 52 1479 1486 Heller AR Rössel T Gottschlich B Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients Int J Cancer 2004 111 611 616 Arshad A Isherwood J Mann C Intravenous ω-3 fatty acids plus gemcitabine JPEN J Parenter Enteral Nutr 2017 41 398 403 Kraft M Kraft K Gärtner S L-carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multi-centre trial Nutr J 2012 11 52 Corish CA Kennedy NP Protein-energy undernutrition in hospital in-patients Br J Nutr 2000 83 575 591 Barker LA Gout BS Crowe TC Hospital malnutrition: prevalence, identification and impact on patients and the healthcare system Int J Environ Res Public Health 2011 8 514 527 Proinflammatory cytokines are drivers of cancer-induced cachexia. Proinflammatory cytokines IL-6 and TNF-α activate downstream signaling of NF-kB and this results in overstimulation of NF-kB and degradation of muscle proteins through the production of catabolic cytokines. Cytokines can also activate the Jak2/STAT3 signaling pathways that can lead to degradation of skeletal muscle protein. TNF-α, tumor necrosis factor α; MuRF1, muscle RING finger-containing protein 1; IL, interleukin.